XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

NCT00272051 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

620

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastases
Colorectal Neoplasms
Colorectal Carcinoma

Interventions

DRUG: SR57746A

Sponsor

Sanofi